

20 April 2016 EMA/186832/2016

Agenda – 3rd Industry stakeholder platform - Operation of the centralised procedure for human medicinal products

21 April 2016, 13:00 - 17.00, Meeting room 03-F

Co-Chairs: Michael Berntgen and Evdokia Korakianiti

Item	Agenda	Time
1.	Welcome / Introductions	10 minutes
	Overview of the agenda	
	Anthony Humphreys, EMA	
2.	MAA evaluation under accelerated assessment	
	Preparing for accelerated assessment: • Better processes to facilitate earlier authorisation Victoria Palmi Reig, EMA Specific expects expecting CVP inspection	15 minutes
	 Specific aspects concerning GxP inspection Andrei Catalin Spinei / Sophia Mylona, EMA 	15 minutes
	Industry experience with the preparation for an accelerated assessment – good practices to share Anne de Bock, EFPIA	20 minutes
	Plenary discussion	20 minutes
3.	Initial practical experience with PRIME eligibility requests	
	Hands-on feedback from preparing request packages Fiona Reekie, EFPIA	10 minutes
	Observations post-launch Jordi Llinares/Zahra Hanaizi, EMA	10 minutes
	Plenary discussion	10 minutes
	Coffee Break	



4.	Pre-submission interactions for MAA submission	45
	Review of recent pre-submission interactions in the centralised procedure and best practices	15 minutes
	Michael Berntgen / Hector Boix Perales, EMA	
	Learnings from applicant's perspectives and potential opportunities for	15 minutes
	improvement Nadege LeRoux, EFPIA	
	Plenary discussion	15 minutes
5.	Updates on operations in the centralised procedure	
	Update on patient involvement in evaluation activities	10 minutes
	Isabelle Moulon, EMA	
	Progress update on improvement actions following the survey on post authorisation procedures	
	Variation management	
	PSUR process / post-authorisation guidanceProcedural support in the post authorisation phase	30 minutes
	Evdokia Korakianiti / Alberto Ganan / Ana Zanoletty, EMA	
	Plenary discussion	
6.	Introduction to the upcoming survey on initial Marketing Authorisation	10 minutes
	procedures Marie-Helene Pinheiro, EMA	
7.		5 minutes
7.	Summary of follow-up items	o minutes
	Close of meeting	
	Enrica Alteri, EMA	

Participants List

EMA

Enrica Alteri, Head of Human Medicines Evaluation Division

Michael Berntgen, Head of Scientific & Regulatory Management Department

Hector Boix Perales, Scientific Officer (Procedure Manager)

Melanie Carr, Head of Stakeholders and Communication Division

Thomas Castelnovo, Head of Evaluation Procedures A (Initial MAA, Extension application, PAM)

Andrei Catalin Spinei, Scientific Administrator (Manufacturing and Quality Compliance)

Zahra Hanaizi, Scientific Officer, Product Development Scientific Support Department

Anthony Humphreys, Head of Procedure Management and Committees Support Division

Alberto Ganan Jimenez, Head of Service for Evaluation Procedures D (type IB variations)

Evdokia Korakianiti, Head of Procedure Management Department

Jordi Llinares, Head of Product Development Scientific Support

Isabelle Moulon, Head of Patients and Healthcare Professionals' Department

Sophia Mylona, Scientific Administrator (Clinical and Non Clinical Compliance)

Victoria Palmi Reig, Scientific Officer (Procedure Manager)

Marie-Helene Pinheiro, Industry Stakeholder Liaison

Agnieszka Szmigiel, Scientific Administrator (Signal Management, Pharmacovigilance Department)

Ana Zanoletty, Scientific Officer (Procedure Manager)

СНМР

Robert Hemmings

European Commission

Dagmar Stara

Industry Stakeholder Organisations

AESGP

Christelle Anquez-Traxler

Mark Griffiths

EBE

Christine Mayer-Nicolai

Chris Walker

EFPIA

Anne de Bock

Nadège Le Roux

Marcello Milano

Eamon O´Loinsigh

Fiona Reekie

Pär Tellner

EUCOPE

Annelise Brossel

Tara Hutton

EuropaBio

Christiane Abouzeid

Emma Du Four

Lise Camilla Hoffmann

Riccardo Mezzasalma

Mireille Muller

Aimad Torqui

Medicines for Europe

Johannes Braun

Tomaž Kralj

Eva Pantau

Beata Stepniewska

Hedley Young

Anna Czwarno Susanne Heiland-Kunath
Susanne Heiland-Kunath